Granahan Investment Management, LLC Fate Therapeutics Inc Transaction History

Granahan Investment Management, LLC

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2022 Feb 14, 2023	BUY	$9.86 - $23.83 $2.72 Million - $6.57 Million	275,734 Added 84.47%	602,153 $6.08 Million
Q3 2022 Nov 14, 2022	BUY	$21.04 - $36.06 $1.33 Million - $2.28 Million	63,263 Added 24.04%	326,419 $7.32 Million
Q2 2022 Aug 15, 2022	BUY	$17.78 - $42.39 $1.03 Million - $2.47 Million	58,211 Added 28.4%	263,156 $6.52 Million
Q1 2022 May 16, 2022	BUY	$29.67 - $60.28 $2.12 Million - $4.31 Million	71,544 Added 53.63%	204,945 $7.95 Million
Q4 2021 Feb 14, 2022	BUY	$47.84 - $64.34 $2.82 Million - $3.79 Million	58,909 Added 79.08%	133,401 $7.81 Million
Q3 2021 Nov 15, 2021	BUY	$59.27 - $95.73 $4.42 Million - $7.13 Million	74,492 New	74,492 $4.42 Million

177

113M

53.7K

Ticker FATE
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 97,000,304
Market Cap $133M
Description
Fate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops programmed cellular immunotherapies for cancer and immune disorders worldwide. Its NK- and T-cell immuno-oncology programs under development include FT516 for the treatment of acute myeloid leukemia (AML) B-cell lymphoma, and advanced solid tumor; FT596 to treat B-cell...

Get notified when there are updates to the investment portfolio of Granahan Investment Management, LLC, based on Form 13F filings with the SEC.

Stay updated on Granahan Investment Management, LLC with notifications on news.